Journal article
Ustekinumab does not increase risk of new or recurrent cancer in inflammatory bowel disease patients with prior malignancy
Abstract
BACKGROUND AND AIM: There is limited data on the rate of new or recurrent cancer in patients with inflammatory bowel disease (IBD) and a history of prior or current malignancy who are initiated on biologic therapies. Furthermore, there is no data on this topic in patients using ustekinumab.
METHODS: The retrospective study included 341 patients with IBD and a history of cancer who were subsequently treated with vedolizumab (VDZ; n = 34), …
Authors
Hasan B; Tandon KS; Miret R; Khan S; Riaz A; Gonzalez A; Rahman AU; Charles R; Narula N; Castro FJ
Journal
Journal of Gastroenterology and Hepatology, Vol. 37, No. 6, pp. 1016–1021
Publisher
Wiley
Publication Date
June 2022
DOI
10.1111/jgh.15806
ISSN
0815-9319